Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 9
Original Research
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 21,427 | Dovepress* | 20,029+ | 2,017 | 22,046 | |
| PubMed Central* | 1,398 | 456 | 1,854 | ||
| Totals | 21,427 | 2,473 | 23,900 | ||
| *Since 30 December 2016 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 2 | 0 | 0 | 0 | 0 | 2 |
View citations on PubMed Central and Google Scholar